KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bionano Genomics (BNGO) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to 115.9%.

  • Bionano Genomics' EBITDA Margin rose 6069900.0% to 115.9% in Q3 2025 from the same period last year, while for Sep 2025 it was 127.94%, marking a year-over-year increase of 2230400.0%. This contributed to the annual value of 337.87% for FY2024, which is 2581100.0% up from last year.
  • Latest data reveals that Bionano Genomics reported EBITDA Margin of 115.9% as of Q3 2025, which was up 6069900.0% from 115.85% recorded in Q2 2025.
  • Bionano Genomics' EBITDA Margin's 5-year high stood at 115.85% during Q2 2025, with a 5-year trough of 1214.98% in Q3 2023.
  • For the 5-year period, Bionano Genomics' EBITDA Margin averaged around 410.86%, with its median value being 444.21% (2021).
  • Its EBITDA Margin has fluctuated over the past 5 years, first plummeted by -7697700bps in 2023, then soared by 6069900bps in 2025.
  • Quarter analysis of 5 years shows Bionano Genomics' EBITDA Margin stood at 456.73% in 2021, then decreased by 0bps to 456.81% in 2022, then skyrocketed by 49bps to 232.75% in 2023, then skyrocketed by 37bps to 146.28% in 2024, then increased by 21bps to 115.9% in 2025.
  • Its EBITDA Margin stands at 115.9% for Q3 2025, versus 115.85% for Q2 2025 and 131.1% for Q1 2025.